A clinical stage company developing small molecules targeting cancers, metabolic, neurodegenerative and autoimmune diseases.

Moleculern™ is a drug discovery platform employed by Biolexis. It screens fragments against a curated protein target library, resulting in 600K empirical data points and scaffold-like compounds for new drug candidate design.

Biolexis utilizes Moleculern™ for rapidly creating, discovering, and developing pre-clinical to clinical stage agents. This approach involves modern chemical biology, advanced machine learning, and AI-backed platforms, facilitating the mapping of hot-spots, computing ligand properties, and building empirical models for active, safe, and efficacious novel chemical entities (NCEs).